Show Summary Details
Page of

The kidney in systemic vasculitis 

The kidney in systemic vasculitis
The kidney in systemic vasculitis

David Jayne


May 30, 2013: This chapter has been re-evaluated and remains up-to-date. No changes have been necessary.


Treatment: (1) Rituximab—discussion of recent clinical trials showing that this chimeric anti-CD20 monoclonal antibody is an effective alternative to cyclophosphamide for remission induction and preferable to further cyclophosphamide for relapsing or refractory disease. (2) Mycophenolate mofetil—evidence that this is less effective than azathioprine for relapse prevention. (3) Other new agents—deoxyspergualin shown to induce remission in refractory Wegener’s granulomatosis in two uncontrolled trials.

Page of

PRINTED FROM OXFORD MEDICINE ONLINE ( © Oxford University Press, 2021. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 24 September 2021

Systemic vasculitis can occur as a primary autoimmune disorder, or as a secondary manifestation of another disease process (e.g. related to infection, malignancy, chronic inflammatory disorder, or drugs). Primary systemic vasculitis is classified according to the predominant size of blood vessel involved and the presence of circulating antineutrophil cytoplasmic autoantibodies (ANCA). Incidence and prevalence rates are between 15 and 20 per million and 200 to 400 per million population, respectively. Vasculitic syndromes frequently involve the kidney, causing tissue infarction, loss of function and rapid progression to end stage renal disease within weeks or months....

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.